Latest publications

Frequency and severity of 192 foods causing food allergy in adults. Kallen EJJ, Welsing PMJ, Nijenhuis I, Van Ree R, Knulst AC, Le TM et al. J Allergy Clin Immunol Glob 2026 Mar; 5(2):100616

Efficacy of abrocitinib and dupilumab in itch-dominant atopic dermatitis: An analysis of 2 trials. Silverberg JI, De Bruin-Weller M, Ortiz de Frutos J, Silvestre JF, Esparza B, Myers DE et al. J Eur Acad Dermatol Venereol 2026 Feb 17

Multi-omics profiling of chronic immune-mediated skin diseases: SKINERGY protocol and strategic evaluation. Koster NG, Van den Reek JMPA, De Jong EMGJ, Van Beugen S, Van Laarhoven AIM, Haeck I et al. J Eur Acad Dermatol Venereol 2026 Feb 06

Addressing potential bias when assessing safety of biologics and JAK inhibitors in atopic dermatitis. Van der Gang LF, Atash K, Zuithoff NPA, Haeck IM, De Graaf M, De Bruin-Weller MS et al. J Eur Acad Dermatol Venereol 2026 Jan 31

Dupilumab Treatment Up to 5 Years Shows No Clinically Meaningful Changes in Laboratory Parameters in Adults with Moderate-to-Severe Atopic Dermatitis. Simpson EL, Bissonnette R, Deleuran M, Nakahara T, Galus R, De Bruin-Weller M et al. Adv Ther 2026 Jan 21

Birch Pollen-Related Food Allergy: Occasionally Severe, Yet Home-Based Oral Food Challenges Are Safe. Kallen EJJ, Bruning AMJ, Blaauw MN, Knulst AC, Van Ree R, Welsing PMJ et al. Clin Exp Allergy 2026 Feb; 56(2):190-192

Continuous monitoring may predict an allergic reaction during an oral food challenge: An exploratory study. Kallen EJJ, Krone T, Verhoeckx KCM, Versluis A, Houben GF, Bijlsma S et al. J Allergy Clin Immunol Pract 2025 Dec 30

Lebrikizumab is efficacious in adults and adolescents with moderate-to-severe atopic dermatitis regardless of atopic comorbidities. Sher ER, Golant A, De Bruin-Weller M, Carrascosa JM, Mehta V, Bieber T et al. Ann Allergy Asthma Immunol 2025 Dec 21

Drug Survival in Atopic Dermatitis: Comparison of Biologics and JAK Inhibitors in the BioDay Registry. Van der Gang LF, Boesjes CM, Zuithoff NPA, Haeck I, Bacoş-Cosma O, Loman L et al. Allergy 2026 Feb; 81(2):609-613

Current treatment landscape of atopic dermatitis focusing on real-world evidence of dupilumab treatment. Boesjes CM, Van der Gang LF, Achten RE, Bakker DS, Van der Rijst LP, Dekkers CC et al. Expert Opin Biol Ther 2025 Nov; 25(11):1171-1192

Targeting OX40: rocatinlimab-a novel therapy for atopic dermatitis. Atash K, Boesjes CM, De Bruin-Weller MS et al. Lancet 2026 Jan 03; 407(10523):4-5

Reassuring evidence on infection risk with dupilumab in atopic dermatitis: Lessons from real-world evidence. Van der Gang LF, De Bruin-Weller MS et al. J Eur Acad Dermatol Venereol 2025 Dec; 39(12):2026-2027

Reading the palms: Palmar hyperlinearity and type 2 biomarkers as early predictors of atopic dermatitis onset in infancy? Vroman F, De Graaf M et al. J Eur Acad Dermatol Venereol 2025 Dec; 39(12):2028-2029

Current treatment practices and efficacy in solar urticaria: insights from a patient survey. Kiefer L, Aulenbacher F, Terhorst-Molawi D, Giménez-Arnau AM, Gonçalo M, Fukunaga A et al. Front Immunol 2025; 16:1683524

Exploring the Disease Duration of Urticaria and Associated Determinants in Primary Care. Soegiharto R, Hengevelt BJ, Boekema-Bakker N, Groenewegen IAM, Knulst AC, Van den Reek JMPA et al. Clin Exp Allergy 2025 Oct 30